45th week of 2013 patent applcation highlights part 38 |
Patent application number | Title | Published |
20130294972 | ZERO-MODE WAVEGUIDE FOR SINGLE BIOMOLECULE FLUORESCENCE IMAGING - The disclosed subject matter provides a zero-mode waveguide (ZMW) including a substrate and at least one nano-well thereon and having a bottom surface and a side wall comprising gold. A surface of the side wall is passivated with a first functional molecule comprising polyethylene glycol. The bottom surface of the nano-well can be functionalized with at least one second molecule comprising polyethylene glycol, for example, a silane-PEG molecule. The second molecule can further include a moiety, such as biotin, which is capable of binding a target biomolecule, which in turn can bind to a biomolecule of interest for single molecule fluorescence imaging analysis. Fabrication techniques of the ZMW are also provided. | 2013-11-07 |
20130294973 | MEASURING ARRANGEMENT FOR OPTICALLY EVALUATING A CHEMICAL REACTION QUANTITATIVELY - The invention relates to a measuring arrangement for optically evaluating a chemical reaction quantitatively, comprising a sample carrier having a carrier layer and a sample layer having an analysis side and a light outlet side opposite the analysis side, and comprising a photosensitive sensor having a plurality of photodetectors on a carrying body and having a transparent surface layer arranged over the photodetectors. A plurality of test sections are arranged on the analysis side at a distance from each other in a longitudinal direction of the sample layer. The analysis side is arranged on the carrier layer in such a way that the test sections face a volume of a microfluidic system. The sample carrier is detachably arranged in an accommodating device, so that the light outlet side faces the photosensitive sensor and the test sections are arranged over the photodetectors. Furthermore, the distance between the test sections and the photodetectors is less than 700 μm. | 2013-11-07 |
20130294974 | AUTOMATIC ANALYZER - A light source radiates light onto a reaction vessel in which a sample is caused to react with a reagent. A transmissive-light receiver, located across from the light source with the reaction vessel located therebetween, measures the intensity of transmissive light passing through the reaction vessel. Scattered-light receivers, located on the side of the transmissive-light receiver, are used to measure the intensities of scattered light and scattered light generated from the reaction vessel. Based on the results of the measurement by the scattered-light receivers, the light intensity of the light source is corrected. This allows correction of the intensity of the light incident on the reaction vessel even when an analysis involves the use of scattered light. The use of such analyzers prevents analysis results from varying from analyzer to analyzer due to inaccurate measurement of the incident light. | 2013-11-07 |
20130294975 | FIBER OPTIC APPARATUS FOR OXYGEN SENSING - An apparatus for oxygen sensing is provided. The apparatus for oxygen sensing includes: a header part to generate interference wave to light generated in a light source by the principle of fiber Fabry-Perot interferometer; and an optical spectrum analyzer to decide existence of oxygen based on change of spectrum periodicity of the above interference wave, in which the header part includes a sensing material of which effective refractive index changes by combination with the oxygen and the above interference wave changes its spectrum periodicity depending on change of effective refractive index of the above sensing material. | 2013-11-07 |
20130294976 | FUEL PROCESSOR - An object of the present invention is to provide a fuel processor that can reduce reforming catalyst deterioration caused by thermal deformation of a structure. The fuel processor includes a reformer | 2013-11-07 |
20130294977 | APPARATUS FOR USE IN PRODUCTION OF NITRIC ACID - A heat exchange apparatus is disclosed for use in the production of nitric acid and which provides for feed-effluent heat exchange and integrated nitrogen dioxide absorption. The apparatus includes a core structure having first and second groups of diffusion bonded corrosion resistant metal plates having fluid flow channel systems formed therein. A feed-effluent heat exchange system is provided by first channel systems of the first and second groups of plates being juxtaposed in heat exchange relationship and an absorption system is provided by second channel systems of the first and second groups of plates being juxtaposed in heat exchange relationship. | 2013-11-07 |
20130294978 | CHEMICAL DISSOLVING DISPENSER - A diluent such as water is sprayed from a nozzle through a screen onto water soluble packages of chemical supported on the screen to produce a solution for treatment of a system. The solution falls into a reservoir and is recirculated through the nozzle onto the screen for a duration sufficient to dissolve a load of chemical into solution. The concentrated solution is dispensed to a system. The reservoir can be flushed into the system before recirculating solution to the nozzle for further chemical dissolving. Chemical-containing packages can be loaded at any time without system interruption. Chemical is supplied in powder or solid form. | 2013-11-07 |
20130294979 | STERILIZATION METHODS AND APPARATUS - Sterilization methods for implantable prostheses are described where a polymeric stent may be sterilized, e.g., via ETO sterilization, at a temperature below a glass transition temperature of the stent. A separate delivery catheter may be sterilized separately and the stent and delivery catheter may then be combined in an aseptic or semi-aseptic environment and sterilized as an assembled system such that the requirements for sterilizing the system are relatively lower. Additionally and/or alternatively, valve and filter assemblies may be used with an optional mandrel assembly for maintaining sterility of the internal components of a catheter system. | 2013-11-07 |
20130294980 | LIQUID CHANNEL DEVICE AND PRODUCTION METHOD THEREFOR - The present invention relates to a liquid channel device capable of easily opening the liquid channel from the closed mode, including a base plate in which a liquid channel, through which a liquid containing at least one of a sample and a reagent, flows, and a metering chamber for holding the liquid, are formed to at least one side thereof, the metering chamber has a liquid transport section for transporting the liquid inside the chamber downstream, and this liquid transport section is operated by means of external pressing on a cover plate in the area opposite the metering chamber. | 2013-11-07 |
20130294981 | LIQUID CHANNEL DEVICE AND PRODUCTION METHOD THEREFOR - The present invention relates to a liquid channel device capable of easily opening the liquid channel from the closed mode, including a base plate in which a liquid channel, through which a liquid containing at least one of a sample and a reagent, flows, and a metering chamber for holding the liquid, are formed to at least one side thereof, the metering chamber has a liquid transport section for transporting the liquid inside the chamber downstream, and this liquid transport section is operated by means of external pressing on a cover plate in the area opposite the metering chamber. | 2013-11-07 |
20130294982 | LIQUID CHANNEL DEVICE AND PRODUCTION METHOD THEREFOR - The present invention relates to a liquid channel device capable of easily opening the liquid channel from the closed mode, including a base plate in which a liquid channel, through which a liquid containing at least one of a sample and a reagent, flows, and a metering chamber for holding the liquid, are formed to at least one side thereof, the metering chamber has a liquid transport section for transporting the liquid inside the chamber downstream, and this liquid transport section is operated by means of external pressing on a cover plate in the area opposite the metering chamber. | 2013-11-07 |
20130294983 | Methods And Apparatus For Isolating Platelets From Blood - A platelet collection device comprising a centrifugal spin-separator container with a cavity having a longitudinal inner surface. A float in the cavity has a base, a platelet collection surface above the base, an outer surface. The float density is below the density of erythrocytes and above the density of plasma. The platelet collection surface has a position on the float which places it below the level of platelets when the float is suspended in separated blood. During centrifugation, a layer of platelets or buffy coat collects closely adjacent the platelet collection surface. Movement of a float having a density greater than whole blood through the sedimenting erythrocytes releases entrapped platelets, increasing the platelet yield. | 2013-11-07 |
20130294984 | Radiochemical Synthesis Apparatus Using Spatial Temperature Manipulation - A compact and flexible apparatus that may be used to carry out multistep chemical or radiochemical synthesis is disclosed. Radiochemical tracers may be synthesized through a spatial temperature manipulation approach. The reaction vessel and the reagent vials can be removed after a single use, suggesting the apparatus can be used multiple times a day. | 2013-11-07 |
20130294985 | Titania-Supported Hydrotreating Catalysts | 2013-11-07 |
20130294986 | SORBENT FORMULATION FOR REMOVAL OF MERCURY FROM FLUE GAS - Methods and systems for reducing mercury emissions from fluid streams having a high concentration of sulfur oxide species are provided herein. In embodiments, mercury is removed from flue gas streams by injecting a dry admixture of a porous mercury adsorptive material and at least one dry agent into the flue gas stream. | 2013-11-07 |
20130294987 | Dry Processes, Apparatus Compositions and Systems for Reducing Mercury, Sulfur Oxides and HCl - Dry processes, apparatus, compositions and systems are provided for reducing emissions of mercury and optionally sulfur oxides and/or HCl. In an embodiment the copper-based mercury remediation composition comprises a copper ammonium complex having an empirical formula of C | 2013-11-07 |
20130294988 | SORPTION APPARATUSES FOR THE PRODUCTION OF PURE GASES - A sorption apparatus for gas purification consists of a vertical flow column with gas tight walls, inlet and outlet filters, and a disintegrator producing reactive powder in the medium of the gas to be purified at ambient temperature, i.e. without forced heating or cooling. A process of sorption purification of gas flow using the sorption apparatus, where the reactive powder is produced as needed by mechanical milling of a monolithic ingot structure in the medium of the gas to be purified and a reactive sorption material. The composition of the sorption material corresponds to an eutectic on the basis of a reactive metal Me or an intermetallic compound MenM with a relatively low melting point, where M is the second metal and n 2:1, wherein the sorption material is obtained according to the above process. | 2013-11-07 |
20130294989 | NITRIC OXIDE OXIDATION OVER SILVER-BASED CATALYSTS | 2013-11-07 |
20130294990 | SILVER PROMOTED CLOSE-COUPLED NOx ABSORBER | 2013-11-07 |
20130294991 | Modified Oxide Supports For Enhanced Carbon Dioxide Adsorbents Incorporating Polymeric Amines - A tunable species removal media including a polymer-impregnated porous material with the introduction of heteroatoms into the porous material during the synthesis of the oxide support. The polymer can be poly(ethyleneimine) (PEI), the porous material a framework of silica nanoparticles, and the heteroatoms selected from Zr, Ti, Fe, Ce, Al, B, Ga, Co, Ca, P, and Ni. The media has a CO | 2013-11-07 |
20130294992 | DRY SCRUBBER SYSTEM - An air quality control system (AQCS) useful for processing a gas stream, such as a flue gas stream emitted from a fossil fuel fired boiler, for at least partial removal of acidic and like pollutants therefrom. The air quality control system includes a CDS reactor useful using a reducing agent slurry. | 2013-11-07 |
20130294993 | Process and Apparatus for Treating a Gas Stream - A process of treating hydrogen gas liberated from the acid or alkaline dissolution of a metal is provided. The process comprises a step of passing the liberated hydrogen gas through a reactor containing an oxidising agent for oxidation of the hydrogen gas into water, followed by a step of regenerating the oxidising agent. Also provided is an apparatus for carrying out the process, the apparatus comprising a reactor containing the oxidising agent, wherein the reactor is at least partially immersed in an alumina bath. | 2013-11-07 |
20130294994 | METHOD FOR PRODUCING PYROPHOSPHATE - A producing method of a high-purity pyrophosphate comprising a calcination of the orthophosphate under the condition of 120° C.-350° C.; and a producing method suitable for manufacturing effectively the high-purity melamine pyrophosphate. | 2013-11-07 |
20130294995 | SELECTIVE SPLITTING OF HIGH ORDER SILANES - The invention relates to a process for preparing monomeric and/or dimeric halogen- and/or hydrogen-containing silicon compounds from oligomeric inorganic silanes having three or more directly covalently interconnected silicon atoms substituted by substituents selected from halogen, hydrogen and/or oxygen by reacting the oligomeric silane over a nitrogen-containing catalyst in the presence of hydrogen halide. | 2013-11-07 |
20130294996 | Method For Treating Substrates With Halosilanes - A method for treating substrates to render them hydrophobic includes penetrating the substrate with a halosilane vapor. | 2013-11-07 |
20130294997 | METHOD FOR PRODUCING FLUORINE COMPOUND | 2013-11-07 |
20130294998 | PROCESS FOR PRODUCING NITRIC ACID - A process for producing nitric acid is disclosed in which a gaseous oxidiser feed composed at least substantially of ammonia, steam and an oxidising gas is exposed to conditions whereby the ammonia is oxidised to produce a reaction mixture including nitrogen monoxide and water vapour. The reaction mixture is then cooled in a heat exchanger whereby: a) the nitrogen monoxide is oxidised and the water vapour is caused to condense, b) the products of the nitrogen monoxide oxidation react with and are absorbed by the condensed water, and c) substantially all of the nitrogen monoxide in the reaction mixture is converted to nitric acid. Also disclosed is a nitric acid solution when produced by the disclosed process. | 2013-11-07 |
20130294999 | METHOD FOR MAKING CARBON NANOTUBE STRUCTURE - The present disclosure relates to a method for making carbon nanotube structure. A substrate having a growing surface is provided. A carbon nanotube layer is placed on the growing surface of the substrate. Part of the growing surface is exposed from the carbon nanotube layer. A number of first catalysts are deposited on surface of the carbon nanotube layer and a number of second catalysts are deposited on the growing surface. A carbon nanotube array is grown on the growing surface and a carbon nanotube cluster is grown on surface of the carbon nanotube layer. | 2013-11-07 |
20130295000 | Nanomaterials and Process for Making the Same - Process for producing nanomaterials such as graphenes, graphene composites, magnesium oxide, magnesium hydroxides and other nanomaterials by high heat vaporization and rapid cooling. In some of the preferred embodiments, the high heat is produced by an oxidation-reduction reaction of carbon dioxide and magnesium as the primary reactants, although additional materials such as reaction catalysts, control agents, or composite materials can be included in the reaction, if desired. The reaction also produces nanomaterials from a variety of other input materials, and by varying the process parameters, the type and morphology of the carbon nanoproducts and other nanoproducts can be controlled. The reaction products include novel nanocrystals of MgO (percilase) and MgAl | 2013-11-07 |
20130295001 | PROCESS FOR PRODUCING SULFUR DIOXIDE AND SULFUR TRIOXIDE | 2013-11-07 |
20130295002 | SELF-REGULATING GAS GENERATOR AND METHOD - A self-regulating gas generator that, in response to gas demand, supplies and automatically adjusts the amount of gas (e.g., hydrogen or oxygen) catalytically generated in a chemical supply chamber from an appropriate chemical supply, such as a chemical solution, gas dissolved in liquid, or mixture. In some embodiments, the gas generator may employ a piston, rotating rod, or other element(s) to expose the chemical supply to the catalyst in controlled amounts. In another embodiment, the self-regulating gas generator uses bang-bang control, with the element(s) exposing a catalyst, contained within the chemical supply chamber, to the chemical supply in ON and OFF states according to a self-adjusting duty cycle, thereby generating and outputting the gas in an orientation-independent manner. The gas generator may be used to provide gas for various gas consuming devices, such as a fuel cell, torch, or oxygen respiratory devices. | 2013-11-07 |
20130295003 | METHOD FOR PRODUCING SODIUM CHROMITE - According to this production method, the water content of a mixture of a chromium oxide (Cr2O3) powder and a sodium carbonate (Na2CO3) powder is brought to 1000 ppm or less, and the mixture is heated in an inert gas atmosphere at a calcination temperature (850 DEG C.) where the sodium carbonate and the chromium oxide undergo a calcination reaction. Sodium chromite is thereby obtained. | 2013-11-07 |
20130295004 | IL-1 BINDING PROTEINS - The present invention describes IL-1β binding proteins, including chimeric, CDR-grafted, and humanized antibodies that bind IL-1β. Binding proteins of the invention have high affinity for IL-1β and neutralize IL-1β activity. A binding protein of the invention can be a full-length antibody or an IL-1β-binding portion thereof. Methods of making and methods of using the binding proteins of the invention are also described. The IL-1β binding proteins of the invention are useful for detecting IL-1β and for inhibiting IL-1β activity, including in a human subject suffering from a disease or disorder in which IL-1β activity is detrimental. | 2013-11-07 |
20130295005 | Combination Therapy With Anti-CD74 Antibodies Provides Enhanced Toxicity to Malignancies, Autoimmune Disease and Other Diseases - Disclosed are compositions and methods comprising combinations of anti-CD74 antibodies with a therapeutic agent that is attached to the anti-CD74 antibody or separately administered. Preferably, the therapeutic agent is an antibody that binds to an antigen different from CD74, such as CD19, CD20, CD21, CD22, CD23, CD37, CD40, CD40L, CD52, CD80, IL-6, CXCR4 or HLA-DR. However, the therapeutic agent may be an immunomodulator, a cytokine, a toxin or other known therapeutic agent. Preferably, the anti-CD74 antibody is part of a DNL complex. More preferably, combination therapy with the anti-CD74 antibody and therapeutic agent is more effective than antibody alone, therapeutic agent alone, or the combination of unconjugated anti-CD74 antibody and therapeutic agent. Administration of combination induces apoptosis of target cells in diseases in which CD74 is overexpressed, such as solid tumors, B-cell lymphomas or leukemias, autoimmune disease, immune dysfunction disease or diabetes. | 2013-11-07 |
20130295006 | PHARMACOKINETIC DETERMINATION OF INTRAVITREAL AGENTS - Compositions and methods for evaluating a pharmacokinetic property of an ophthalmic agent administered by intravitreal injection are provided. | 2013-11-07 |
20130295007 | ANTI-PMEL17 ANTIBODIES AND IMMUNOCONJUGATES - The invention provides anti-PMEL17 antibodies and immunoconjugates and methods of using the same. | 2013-11-07 |
20130295008 | Alpha Emitting Constructs and Uses Thereof - The present invention discloses methods for treating non-malignant cell diseases by administering to an individual a construct comprising actinium-225 or bismuth-213 and an antigen of a non-malignant cell. Also, provided is a method for treating a solid tumor associated with an abnormal proliferation of cells by targeting an antigen of the tumor-associated vasculature with the constructs. | 2013-11-07 |
20130295009 | METHOD OF TREATING INFLAMMATION - The present invention relates to the use of compounds of general formula (I) as ligands to the melanocortin receptors and/or for treatment of disorders in the melanocortin system: | 2013-11-07 |
20130295010 | HER2 BINDING PEPTIDES LABELLED WITH A 18F - CONTAINING ORGANOSILICON COMPOUND - Imaging agents comprising an isolated polypeptide conjugated with a radionucleide and a chelator; wherein the isolated polypeptide binds specifically to HER2, or a variant thereof; and methods for preparing and using these imaging agents. | 2013-11-07 |
20130295011 | BACTERIAL NITROREDUCTASE ENZYMES AND METHODS RELATING THERETO - The invention relates generally to bacterial nitroreductase enzymes and methods of use thereof: More particularly, although not exclusively, said enzymes have use in non-invasive imaging techniques, monitoring of therapeutic cell populations and gene-directed enzyme prodrug therapy. The invention also relates to the use of bacterial nitroreductase enzymes in radioimaging and/or ablation of biological agents and to compositions of use in such methods. | 2013-11-07 |
20130295012 | SHEAR CONTROLLED RELEASE FOR STENOTIC LESIONS AND THROMBOLYTIC THERAPIES - The invention provides compositions and methods for treating or imaging stenosis, stenotic lesions, occluded lumens, embolic phenomena or thrombotic disorders. The invention further provides compositions and methods for treating internal hemorrhage. | 2013-11-07 |
20130295013 | SOLID COMPOSITION FOR THE ORAL ADMINISTRATION OF DYES AND DIAGNOSTIC USE THEREOF - The present application discloses solid compositions for the oral administration of dyes, and diagnostic use thereof. Preferably, such diagnostic use is aimed at the diagnostic evaluation of the gastrointestinal tract. | 2013-11-07 |
20130295014 | METHODS FOR TREATING AND DIAGNOSING BLINDING EYE DISEASES - This invention relates to, in part, methods and compositions that are useful for the diagnosis, treatment, or prevention of a blinding eye disease, including in the discovery of drugs that are efficacious against these diseases. Diseases include, for example, age related macular degeneration and reticular pseudodrusen disease, and the methods described herein include, for example, the method named delayed near infrared analysis (DNIRA). | 2013-11-07 |
20130295015 | Optically-Controlled CNS Dysfunction - Provided herein are animals expressing light-responsive opsin proteins in the basal lateral amygdala of the brain and methods for producing the same wherein illumination of the light-responsive opsin proteins causes anxiety in the animal. Also provided herein are methods for alleviating and inducing anxiety in an animal as well as methods for screening for a compound that alleviates anxiety in an animal. | 2013-11-07 |
20130295016 | SIGNATURES OF ELECTROENCEPHALOGRAPHIC OSCILLATIONS - The present invention provides, in some aspects, methods for identifying and evaluating signatures in electroencephalographic oscillations that occur during onset of an exploratory activity in a subject. | 2013-11-07 |
20130295017 | METHODS FOR SCREENING ANTIBIOTIC COMPOUNDS - The present invention is a method for screening drugs or antibiotic activity by screening a drug for activity to disrupt a toxin-antitoxin complex in a bacterial cell. | 2013-11-07 |
20130295018 | LIQUID PREPARATION FOR ORAL ADMINISTRATION USED FOR CT COLONOGRAPHY AND COMPOSITION FOR GASTROINTESTINAL RADIOGRAPHY - The present invention provides a liquid preparation for oral administration that is capable of reducing the amount of colonic irrigation solution taken during gastrointestinal pretreatment and decreasing the burden on the subject without sacrificing test accuracy and without prolonging the time required for pretreatment, and a composition for gastrointestinal radiography used to prepare the liquid preparation for oral administration. Namely, provided are a liquid preparation for oral administration taken during gastrointestinal imaging by CT colonography that comprises an iodine compound and a water-soluble polymer or saline laxative, wherein 300 mL to 1200 mL are taken on the day before CT colonography in a single administration or divided among several administrations, and a composition for gastrointestinal radiography comprising an iodine compound and a water-soluble polymer or saline laxative, wherein 300 mL to 1200 mL are taken in the form of an aqueous solution, having an iodine content of 3.5 mg/mL to 90 mg/mL prepared by dissolving in water, on the day before CT colonography in a single administration or divided among several administrations. | 2013-11-07 |
20130295019 | LIGANDS AND METHODS FOR LABELING BIOMOLECULES IN VIVO - Disclosed are tris(triazolylmethyl)amine ligands, and kits and methods for labeling and/or imaging a biomolecule of interest in a subject or living system. | 2013-11-07 |
20130295020 | Radiopaque Embolic Particles - A radiopaque particulate material one or more of SiO | 2013-11-07 |
20130295021 | HUMAN ANTI-TAU ANTIBODIES - Provided are human tau-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for tau are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for tau targeted immunotherapy and diagnosis, respectively. | 2013-11-07 |
20130295022 | Moisturizing Foam Containing Lanolin - The present invention provides a highly tolerable, hydrating lanolin containing foamable composition for administration to the skin, body surface, body cavity or mucosal surface, e.g., the mucosa of the nose, mouth, eye, ear, respiratory system, vagina or rectum. The foamable composition includes lanolin, a surface-active agent, about 0.01% to about 5% by weight of at least one polymeric additive selected from the group consisting of a bioadhesive agent, a gelling agent, a film forming agent and a phase change agent, water, and a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition. | 2013-11-07 |
20130295023 | Inhalation Solutions - A inhaler for an inhalation formulation, comprising a canister containing a pharmaceutical composition under pressure; a metering valve for measuring a metered dose of the composition from the canister for administration to a patient in need thereof; and an actuator for actuating discharge of the metered dose to the patient; wherein the actuator includes a discharge orifice having a diameter in the range 0.2 to 0.4 mm; and wherein the pharmaceutical composition comprises an anticholinergic agent and a pharmaceutically acceptable propellant. | 2013-11-07 |
20130295024 | AEROSOL EMULSIONS - The present invention relates to water-in-oil aerosol emulsion compositions and related methods and, in particular, to aerosol emulsions containing an active agent. In some embodiments, the aerosol emulsion comprises a propellant dissolved in the oil phase. | 2013-11-07 |
20130295025 | USE OF BETA-ADRENERGIC INVERSE AGONISTS FOR SMOKING CESSATION - The chronic use of p-adrenergic inverse agonists such as nadolol, carvedilol, and ICI-118,551 provides an improved method for the treatment of mucus hypersecretion in subjects with such mucus hypersecretion. One aspect of a method according to the present invention is a method of preventing or controlling mucus hypersecretion in the respiratory tract comprising administering a therapeutically effective quantity of a p-adrenergic inverse agonist to a subject with mucus hypersecretion or at risk of mucus hypersecretion. The invention further encompasses pharmaceutical compositions comprising the p-adrenergic inverse agonist and the additional compound. | 2013-11-07 |
20130295026 | FAST DISINTEGRATING COMPOSITIONS COMPRISING NABILONE AND RANDOMLY METHYLATED BETA CYCLODEXTRIN - The present invention provides a novel composition comprising Nabilone and randomly methylated B-cyclodextrin (RAMEB), wherein the weight ratio (dry weight to dry weight) between Nabilone and RAMEB is about 1:60-1:140. The present invention further provides methods for increasing the bioavailability of Nabilone. | 2013-11-07 |
20130295027 | ORAL CARE COMPOSITION - The present invention relates to an oral care composition and a method of disinfecting the oral cavity. So far synthetic material (e.g. Triclosan) has been used which is believed by many consumers to be harsh on them. Consumers, more and more prefer using products that contain natural materials. Further, in many countries, culturally or otherwise, people are reluctant to using alcohol in their mouthwashes. The present inventors have been working on solving these problems and have come up with an oral care composition which includes natural materials that are found to interact synergistically with certain metal salts in killing | 2013-11-07 |
20130295028 | Emulsified MQ Resin: Compositions And Methods - Long term stable, oil-in-water emulsions that have a high concentration of plasticized MQ-type resin and/or its derivatives in an internal phase. Also, novel compositions for topical use that comprise our MQ resin emulsions. These compositions include, hair care products, especially for treating split ends, skin care products, such as sunscreens, and systems for delivering actives to skin and hair. In some preferred embodiments, the MQ emulsion is stabilized in such a way that the surface tension of the emulsion is sufficiently close to the surface tension of a target surface, such as damaged hair or skin. | 2013-11-07 |
20130295029 | Personal Care Product and Manufacture Thereof - Disclosed is a package for a personal care composition, the package comprising a container containing a personal care composition, the container having a base comprising a base face for standing the package on a planar surface, and a cap removably connected to and covering a dispensing end of the container opposite to the base. The cap has an end face which is inclined to the base face, and the container and cap are shaped to permit the package, independent of the amount of the personal care composition contained within the container, selectively to be stood on the base face in an upright orientation on the planar surface or on the end face in an inverted orientation on the planar surface. | 2013-11-07 |
20130295030 | HAIR TREATMENT AGENT COMPOSITION - The present invention relates to a hair treatment composition capable of imparting good finger combability, body and manageability to the hair treated therewith and dried, and to a method for producing the composition. The hair treatment composition contains a cationized hydroxypropyl cellulose (A) and at least one treating agent (B) selected from a hair-coloring dye, an oxidizing agent, an alkali agent and a keratin-reducing agent. | 2013-11-07 |
20130295031 | COSMETIC COMPOSITION AND PROCESS FOR CURLING KERATIN FIBRES - The present invention relates to a cosmetic composition for coating keratin fibres, and especially the eyelashes, comprising: a polymer, derived from the (co-) (homo-)polymerization of (poly)cyclic monomers with a glass transition temperature (Tg) of greater than or equal to 80° C. and a weight-average molecular mass (Mw) of greater than 80 000 g/mol, the said (poly)cyclic monomers comprising (meth)acrylate monomers of formula H | 2013-11-07 |
20130295032 | BLOCK POLYMERS, COMPOSITIONS AND METHODS FOR USE FOR FOAMS, LAUNDRY DETERGENTS, AND SHOWER RINSES AND COAGULANTS - The present invention relates to a block polymeric material. Typically the block polymer comprises units capable of having an average cationic charge density of about 15 or less, preferably 5 or less, more preferably from about 0.05 to about 5, even more preferably from about 0.05 to about 2.77, even more preferably from about 0.1 to about 2.75, most preferably from about 0.75 to about 2.25 units per 100 daltons molecular weight at a pH of from about 4 to about 12. The polymeric material is a suds enhancer and a suds volume extender for personal care products such as soaps and shampoos. The compositions have increased effectiveness for preventing re-deposition of grease during hand and body washing. The polymers are also effective as a soil release agent in fabric cleaning compositions. The polymeric material is also effective in oil well treating foam, fire-fighting foam, hard surface cleaning foam, shaving cream, post-foaming shaving gel, dephiliatories and as a coagulant/retention aid for titanium dioxide in paper making. | 2013-11-07 |
20130295033 | HAIR COSMETIC - The present invention relates to a hair cosmetic capable of giving good finger combability and manageability with no oily feeling to the hair treated therewith and dried, and to a method for producing the hair cosmetic. The hair cosmetic contains a cationized hydroxypropyl cellulose (A), an oil (B) of which the amount of dissolution in 100 g of water at 20° C. is from 0 to 1 g, and a surfactant (C), wherein the cationized hydroxypropyl cellulose (A) has an anhydroglucose-derived main chain and has a degree of substitution with cationized ethyleneoxy group of from 0.01 to 2.9 and a degree of substitution with propyleneoxy group of from 0.1 to 4.0, and the production method is for producing the hair cosmetic. | 2013-11-07 |
20130295034 | AGENT FOR FIBERS CONTAINING KERATIN, CONTAINING AT LEAST ONE SPECIFIC AMPHIPHILIC CATIONIC POLYMER AND AT LEAST ONE ADDITIONAL FILM-FORMING CATIONIC AND/OR STABILIZING POLYMER - Agent for treating fibers containing keratin, particularly human hair, comprising, in a cosmetically acceptable carrier: (a) at least one amphiphilic, cationic polymer having at least one structural unit of formulae (I) to (IV), wherein; R | 2013-11-07 |
20130295035 | COSMETIC COMPOSITION FOR EYELASHES - The present invention relates to a cosmetic composition for eyelashes such as a mascara, comprising: at least one anionic surfactant including 2-amino-2-methyl-1,3-propanediol in combination with a C | 2013-11-07 |
20130295036 | METHOD OF USING WOOD EXTRACTS IN COSMETIC AND HYGIENE PRODUCTS - A method of using wood extracts as natural compounds in cosmetic and hygiene products. In particular, the method includes using natural compounds derived from a plant material wherein the compounds are at least one of antioxidant Dihydroquercetin (taxifolin), polysaccharide Arabinogalactan, Arabinogalactan combined with Dihydroquercetin (taxifolin) and wood oleoresin comprising oil and resin, and wherein all these natural compounds are consequently extracted from wood and\or by-products of logging industry. | 2013-11-07 |
20130295037 | IN SITU BONDS - A biocompatible tissue-bonding adhesive composition having a polyol of functionality N. The polyol being terminated has at least one polyisocyanate in solution with at least (N−1) % of the solution having free polyisocyanate. N may be in the range 1.5-8. The polyol may be a branched polypropylene/polyethylene oxide copolymer. | 2013-11-07 |
20130295038 | Cross-Linked Copolymer Containing Phosphorylcholine Monomer and Cosmetic Composition Containing Same - Disclosed is a copolymer containing an α,β-ethylenically unsaturated monomer, a phosphorylcholine monomer, and a cross-linking agent as a monomer. Also disclosed are a cosmetic composition containing the copolymer and a cosmetic material using the cosmetic composition. | 2013-11-07 |
20130295039 | POLYMER CONJUGATES WITH A LINKER - This application relates generally to biocompatible water-soluble polymers with pendant functional groups and methods for making them, and particularly to polyglutamate amino acid conjugates that can include a linker to a compound that can include a drug, and their use for a variety of drug delivery applications, e.g., anticancer. | 2013-11-07 |
20130295040 | POLYMER - The application provides a method of producing a comb polymer comprising the steps of:
| 2013-11-07 |
20130295041 | Novel Composition - An oral care compositon is described for use in the treatment or alleviation of the symptoms of dry mouth comprising polyvinyl pyrrolidone (PVP) or a derivative thereof, an anionic mucoadhesive polymer and an orally acceptable carrier or excipient. | 2013-11-07 |
20130295042 | Peptides and Peptide Mimetics to Treat Pathologies Associated With Eye Disease - This invention provides novel active agents (e.g. peptides, small organic molecules, amino acid pairs, etc.) peptides that ameliorate one or more symptoms of eye disease and/or other pathologies characterized by an inflammatory response. In certain embodiment, the peptides resemble a G* amphipathic helix of apolipoprotein J. The agents are highly stable and readily administered via an oral route or via intraocular injection. | 2013-11-07 |
20130295043 | VACCINATION IN ELDERLY PATIENTS - The present invention relates to vaccines comprising at least one mRNA encoding at least one antigen for use in the treatment of a disease in an elderly patient preferably exhibiting an age of at least 50 years, more preferably of at least 55 years, 60 years, 65 years, 70 years, or older, wherein the treatment comprises vaccination of the patient and eliciting an immune response in said patient. The present invention is furthermore directed to kits and kits of parts comprising such a vaccine and/or its components and to methods applying such a vaccine or kit. | 2013-11-07 |
20130295044 | NATURAL KILLER CELLS WITH ENHANCED IMMUNE RESPONSE - The invention relates to a specialized subpopulation of natural killer cells that have enhanced effector functions and the potential to kill malignant tumor cells or infected cells when the natural killer cells are exposed to an antibody bound to the tumor cells or the infected cells. | 2013-11-07 |
20130295045 | MEDICAMENT COMPRISING RECOMBINANT ANTIBODY AGAINST CHEMOKINE RECEPTOR CCR4 - A medicament having a higher therapeutic effect than that provided by administration of a recombinant antibody against human CC chemokine receptor 4 or an antibody fragment thereof or an agent alone is provided. | 2013-11-07 |
20130295046 | INTERLEUKIN-13 RECEPTOR ALPHA 2 PEPTIDE-BASED BRAIN CANCER VACCINES - Provided herein are interleukin-13 receptor α2 peptide-based brain cancer vaccines and methods for treating and vaccinating against brain cancer comprising administering to patients in need thereof interleukin-13 receptor α2 peptide-based brain cancer vaccines. Also provided herein are regimens comprising interleukin-13 receptor α2 peptides and at least one additional peptide and/or immunostimulant. | 2013-11-07 |
20130295047 | CLIP MODULATION FOR THE TREATMENT OF MUCOSAL DISEASES - The disclosure relates to methods for treating disorders of the mucosal tract such as the gastrointestinal system by targeting CLIP molecules. The methods are based on that CLIP in the groove of MHC class I or II molecules of the cells lining the mucosal surfaces of the body, such as the gastrointestinal tract, provides protection from MHC Class II or MHC class I mediated cell death, and therefore are useful for treating, inhibiting the development of a multitude of illnesses and conditions of the mucosal tract, including autoimmune disease. | 2013-11-07 |
20130295048 | CRYSTALLINE FORM OF A PYRIDYL-PIPERAZINYL HEPATITIS C VIRUS INHIBITOR - The invention provides crystalline solid forms of (((S)-1-{(S)-2-[4-(4′-{[6-((2R,5S)-2,5-dimethyl-4-methylcarbamoyl-piperazin-1-yl)-pyridine-3-carbonyl]-amino}-2′-trifluoromethoxy-biphenyl-4-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester. The invention also provides pharmaceutical compositions comprising such crystalline solid forms, methods of using such crystalline solid forms to treat hepatitis C virus infection, and processes useful for preparing such crystalline solid forms. | 2013-11-07 |
20130295049 | LINKED DIBENZIMIDAZOLE ANTIVIRALS - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 2013-11-07 |
20130295050 | ANTI-IGF-I RECEPTOR ANTIBODIES, DNAS, VECTORS, HOST CELLS AND GENETIC CONSTRUCTS - DNAs, vectors, host cells and genetic constructs of antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of these molecules with cytotoxic agents, which specifically bind to and inhibit insulin-like growth factor-I receptor, antagonize the effects of IGF-I and are substantially devoid of agonist activity toward the insulin-like growth factor-I receptor. These molecules can be conjugated to cytotoxic agents for use in the treatment of tumors that express elevated levels of IGF-I receptor, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma and pancreatic cancer. These molecules can also be labeled for in vitro and in vivo diagnostic uses, such as in the diagnosis and imaging of tumors that express elevated levels of IGF-I receptor. | 2013-11-07 |
20130295051 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT - The present invention relates to compounds and compositions for the inhibition of NAMPT, their synthesis, applications and antidotes. An illustrative compound of the invention is shown below. | 2013-11-07 |
20130295052 | NOVEL CONJUGATES FOR TARGETED DRUG DELIVERY - The present invention relates to a novel drug delivery system comprising a drug(s)-protein-polymer triple conjugate. The triple conjugate employs a (i) protein moiety capable of binding selectively to a particular target site possessed by a cell/affected organ, (ii) a polymer moiety, covalently linked to the protein and (iii) an active drug moiety that includes one or more drug(s) covalently linked to either said polymer moiety or to a protein moiety. The conjugates of the present invention have target specificity and better selectivity to a defined population of cells/organs(s). The present invention further relates to methods of preparation and methods of treatment comprising administering said conjugate as a single unit. The conjugates of the present invention are usefully employed in therapeutic as well as non-therapeutic, e.g., diagnostic applications. | 2013-11-07 |
20130295053 | Methods of Producing Adenovirus Vectors and Viral Preparations Generated Thereby - The present invention, in some embodiments thereof, relates to methods of producing adenoviruses such as pro- and anti-angiogenic adenovirus vectors and preparations generated there by. Particularly, in some embodiments, the viral vectors comprise a heterologous pro- or anti-angiogenic gene under the transcriptional control of the murine pre-proendothelin promoter (e.g. PPE-1-3X), for targeted expression of in angiogenic endothelium. | 2013-11-07 |
20130295054 | Modified Bacteria and their Uses thereof for the Treatment of Cancer or Tumor - Described herein is a method of treatment of cancer or tumor using a modified bacteria or composition comprising the modified bacteria. In certain embodiments, the method is in combination with other treatment. In certain embodiments, the treatment is chemotherapy, radiation therapy, gene therapy, surgery or a combination thereof. The method makes modified facultative anaerobic bacteria into a conditional obligate anaerobe. The modified bacteria are strictly hypoxia regulated and comprise an essential gene expressing cassette. The vectors of this method comprise the essential gene expressing cassette. Also described herein are therapeutic and prophylactic compositions comprising the modified bacteria. The therapeutic and prophylactic compositions contain a purified form of the modified bacteria, while in certain embodiments, they do not contain other strain of microorganisms. The modified bacteria grow within the solid tumor/cancer, retarding its growth and are rapidly eliminated from normal tissues. The solid tumor/cancer includes breast cancer, liver cancer or neuroblastoma. | 2013-11-07 |
20130295055 | PROBIOTIC COMPOSITION FOR LIVESTOCK, AND METHOD FOR PREPARING SAME - The present invention relates to an eco-friendly probiotic composition, and more particularly, to a probiotic composition for livestock production, comprising a lactic acid bacteria culture medium and an organic acid, wherein the organic acid is contained in an amount of 0.002 to 0.1 parts by weight relative to 1 parts by weight of the lactic acid bacteria culture medium. The present invention also relates to a method for preparing the composition. The eco-friendly probiotic composition of the present invention does not contain antibiotics and may exhibit complex effect of sterilization and virucidal effectiveness. | 2013-11-07 |
20130295056 | Generation of Histocompatible Tissues Using Nuclear Transplantation - Tissues produced by culture of cells produced by nuclear transfer on a matrix derived from nuclear transfer embryos or embryos and pluripotent cells provided by other methods are provided. These tissues are useful for cell therapy. | 2013-11-07 |
20130295057 | EN VIVO GENERATED TISSUE SYSTEM - The present invention relates to methods of generating an ex vivo tissue-like system in a bioreactor system capable of supporting continuous production of, and output of cells and tissues and an ex vivo tissue system made therefrom. | 2013-11-07 |
20130295058 | Pharmaceutical Compositions Comprising Gingiva A-Derived Mesenchymal Stem Cells and Methods of Treating Inflammation, Wound Healing and Contact Hypersensitivity - Disclosed are methods of polarizing macrophages to exhibit M2 phenotype, including introducing an effective amount of gingiva-derived mesenchymal stem cells to an environment comprising a population of macrophages such that the macrophages are in fluid communication with the gingiva-derived mesenchymal stem cells. Also disclosed are methods of promoting cutaneous wound healing including administering to a patient an effective amount of human gingiva-derived mesenchymal stem cells, thereby resulting in at least one of accelerated wound closure, rapid re-epithelialization, improved angiogenesis and improved tissue remodeling relative to untreated controls. Also disclosed are methods for attenuating contact hypersensitivity in a patient, the methods including administering to a patient an effective amount of human gingiva-derived mesenchymal stem cells at a time at least timeframe selected from the group consisting of before sensitization, after sensitization and before challenge and after challenge, thereby attenuating contact hypersensitity. | 2013-11-07 |
20130295059 | RHODAMINE DERIVATIVES FOR PHOTODYNAMIC DIAGNOSIS AND TREATMENT - Compositions and methods for reducing or preventing graft-versus-host disease associated with allogeneic stem cell transplantation are described. A method includes harvesting hematopoietic cells from a patient with an immunologic disorder and harvesting hematopoietic cells from a donor. The harvested hemaptopoietic cells from the patient and the donor are mixed ex vivo for a period of time sufficient to activate lymphocytes within the hematopoietic cells harvested from the donor such that an immune reaction occurs and an activated portion and an unactivated portion is produced. A rhodamine B derivative is then added to the mixture of cells and the mixture is irradiated at a suitable wavelength and intensity for the selective destruction and/or inactivation of the activated portion without substantially affecting the unactivated portion or causing systemic toxicity in said patient. The irradiated cells are then infused into the patient. | 2013-11-07 |
20130295060 | METHOD FOR CULTURING CARDIAC PROGENITOR CELLS AND USE OF CARDIAC PROGENITOR CELLS - Disclosed is a method for culturing myocardium-resident cardiac progenitor cells, comprising: embedding myocardial fragments into hydrogel; culturing the myocardial fragment into hydrogel; degrading only the hydrogel to recover cardiac progenitor cells grown out of the myocardial fragment to the hydrogel; and amplifying the cardiac progenitor cells in vitro. Also, the cardiac progenitor cells, a method for differentiating the same, and the use thereof as cell therapeutic agent for heart diseases are provided. In addition to possessing the potential to differentiate into cardiomyocytes, osteoblasts, adipocytes, chondrocytes, vascular endothelial cells, smooth muscle cells, neural cells, and skeletal muscle cells, the myocardium-resident cardiac progenitor cells can spontaneously differentiate into cardiomyocytes even in the absence of a special differentiation inducing agent. Thus, the cardiac progenitor cells can be used to produce bio-active medicines such as cell therapeutics and tissue engineering therapeutics with high industrial applicability. | 2013-11-07 |
20130295061 | Dosage Unit Formulations of Autologous Dermal Fibroblasts - Dosage units consist of an autologous cell therapy product composed of fibroblasts grown for each individual to be treated. The suspension of autologous fibroblasts, grown from a biopsy of each individual's own skin using current good manufacturing practices (CGMP), and standard tissue culture procedures, is supplied in vials containing cryopreserved fibroblasts or precursors thereof, having a purity of at least 98% fibroblasts and a viability of at least 85%, for administration of from one to six mL, preferably two mL, of cells at a concentration of from 1.0-2.0×10 | 2013-11-07 |
20130295062 | METHODS AND COMPOSITIONS FOR TREATMENT OF ALZHEIMER'S DISEASE - The present invention relates to methods and compositions for use in the treatment of neurological disorders, such as Alzheimer's disease and dementia. In one embodiment, the present invention provides a method of treatment of Alzheimer's disease in an individual by administering a composition overexpressing ACE to the individual. In another embodiment, the method of treatment comprises administering a composition comprising a therapeutically effective dosage of ACE. | 2013-11-07 |
20130295063 | HIGH AFFINITY HIV T CELL RECEPTORS - The present invention provides TCRs having high affinity. The TCR binds to SLYNTVATL (SEQ ID NO:16)-HLA-A*0201 with a K | 2013-11-07 |
20130295064 | CARDIAC INDUCED PLURIPOTENT STEM CELLS AND METHODS OF USE IN REPAIR AND REGENERATION OF MYOCARDIUM - Cardiac myocyte differentiation reported thus far is from iPS cells generated from mice and human fibroblasts. iPS cells from cardiac or ventricular specific cell types are generated herein having the potential to repair and regenerate infarcted myocardium. The cells were transduced with four sternness factors and reprogrammed them into iPS cells. These cardiac iPS cells were able to differentiate into beating cardiac myocytes, formed cardiac-specific structures, and positively stained for cardiac specific proteins. Transplanted cells also significantly inhibited apoptosis and fibrosis and improved cardiac function. | 2013-11-07 |
20130295065 | NUCLEIC ACID CONSTRUCT FOR EXPRESSION OF ALPHA-GALACTOSIDASE IN PLANTS AND PLANT CELLS - Nucleic acid expression constructs are provided and, more particularly, nucleic acid constructs for expression of human alpha-galactosidase in plant cells, cells expressing the nucleic acid construct, producing the human alpha-galactosidase and uses thereof. | 2013-11-07 |
20130295066 | METALLO-LACTOFERRIN-COENZYME COMPOSITIONS FOR DETOXIFICATION SUPPORT - Formulations are provided for detoxification support. The formulations generally include a trigger complex, an elemental complex and a coenzyme-vitamin B complex. The trigger complex is high in fiber such as glucomannan and includes Metallo-Lactoferrin protein in an alkaline buffer system. The elemental complex includes one or more trace element as a suitable salt. The coenzyme-vitamin B complex includes one or more coenzyme, coenzyme precursor and/or B-vitamin. The compositions may optionally include additional components such as Lactic Acid bacteria, L-theanine, cranberry root extract, tumeric root extract, inulin and blond psyllium. The compositions can be administered orally in a variety of forms. | 2013-11-07 |
20130295067 | MICROORGANISMS AND METHODS FOR TREATING POULTRY - An isolated | 2013-11-07 |
20130295069 | METALLO-LACTOFERRIN-COENZYME COMPOSITIONS AND METHODS FOR WEIGHT MANAGEMENT - Formulations are provided for the management of weight. The formulations generally include a trigger complex, an elemental complex and a coenzyme-vitamin B complex. The trigger complex is high in fiber such as glucomannan and includes Metallo-Lactoferrin protein in an alkaline buffer system. The elemental complex includes one or more trace element as a suitable salt. The coenzyme-vitamin B complex includes one or more coenzyme, coenzyme precursor and/or B-vitamin. The compositions may optionally include additional components such as dihydroxy acetone (DHA), inositol, 5-hydroxy-L-tryptophan (5-HTP), choline, milk protein hydrolysate, and pyruvate. The compositions can be administered orally in a variety of forms and may substitute for one or more meals per day to manage weight. | 2013-11-07 |
20130295070 | PROTEASE STABLE CELL WALL LYSING ENZYMES - The present invention relates to a modified polypeptide with a biological activity to lyse cell walls of bacteria, wherein the polypeptide has no caspase, clostripain, enterokinase, factor Xa, granzyme B, | 2013-11-07 |
20130295071 | METHODS AND COMPOSITIONS FOR CNS DELIVERY OF B-GALACTOCEREBROSIDASE - The present invention provides, among other things, compositions and methods for CNS delivery of lysosomal enzymes for effective treatment of lysosomal storage diseases. In some embodiments, the present invention includes a stable formulation for direct CNS intrathecal administration comprising an B-Galactocerebrosidase protein, salt, and a polysorbate surfactant for the treatment of GLD Disease. | 2013-11-07 |
20130295072 | LONG-ACTING COAGULATION FACTORS AND METHODS OF PRODUCING SAME - Polypeptides comprising at least one carboxy-terminal peptide (CTP) of chorionic gonadotrophin attached to the carboxy terminus but not to the amino terminus of a coagulation factor and polynucleotides encoding the same are disclosed. Pharmaceutical compositions comprising the polypeptides and polynucleotides of the invention and methods of using and producing same are also disclosed. | 2013-11-07 |